参考文献/References:
[1] Matsuo A,Nagai-Okatani C,Nishigori M,et al.Natriuretic peptides in human heart: Novel insight into their molecular forms, functions, and diagnostic use[J]. Peptides,2019,111:3-17.
[2] Inoue K,Naruse K,Yamagami S,et al.Four functionally distinct C-type natriuretic peptides found in fish reveal evolutionary history of the natriuretic peptide system[J].Proc Natl Acad Sci U S A ,2011,100(17):10079-10084.
[3] Del RS,Cabiati M,Lionetti V,et al.NPR-B, the C-type natriuretic peptide specific receptor,is the predominant biological receptor in mouse and pig myocardial tissue[J].Minerva Endocrinol,2010,35(2):37-46.
[4] Osterbur K,Yu D,Declue AE.Interleukin-1β, tumour necrosis factor-α and lipopolysaccharide induce C-type natriuretic peptide from canine aortic endothelial cells[J].Res Vet Sci,2013,94(3):478-483.
[5] Wong PCY,Guo J,Zhang A.The renal and cardiovascular effects of natriuretic peptides[J].Adv Physiol Educ,2017,41(2):179-185.
[6] Izumiya Y,Araki S,Usuku H,et al.Chronic c-type natriuretic peptide infusion attenuates angiotensin Ⅱ-induced myocardial superoxide production and cardiac remodeling[J].International Journal of Vascular Medicine,2012,2012:1-9.
[7] Sangaralingham SJ,Huntley BK,Martin FL,et al.The aging heart, myocardial fibrosis,and its relationship to circulating c-type natriuretic peptide[J].Hypertension,2011,57(2):201-207.
[8] Richards AM.C-type natriuretic peptide and cardiac fibrosis[J].Hypertension,2011,57(2):154-155.
[9] Langenickel TH,Buttgereit J,Pagel-Langenickel I,et al.Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B[J].Proc Natl Acad Sci U S A ,2006,103(12):4735-4740.
[10] Calvieri C,Rubattu S,Volpe M.Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides[J].J Mol Med(Berl),2012,90(1):5-13.
[11] Prentki ES,Caniffi C,Bouchet G,et al.C-type natriuretic peptide chronic administration attenuates cardiac fibrosis and inflammation in spontaneously hypertensive rats[J].BMC Pharmacology and Toxicology,2015,16(S1):A104.
[12] Day A,Jameson Z,Hyde C,et al.C-type natriuretic peptide (CNP) inhibition of interferon-γ-mediated gene expression in human endothelial cells in vitro[J].Biosensors,2018,8(3):86-97.
[13] Bae C,Hino J,Hosoda H,et al.Overexpression of c-type natriuretic peptide in endothelial cells protects against insulin resistance and inflammation during diet-induced obesity[J].Sci Rep,2017,7(1):9807-9819.
[14] Bubb KJ,Aubdool AA,Moyes AJ,et al.Endothelial c-type natriuretic peptide is a critical regulator of angiogenesis and vascular remodeling[J].Circulation, 2019,139(13):1612-1628.
[15] Fu S,Ping P,Wang F,et al.Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure[J].J Biol Eng, 2018,12:2. doi: 10.1186/s13036-017-0093-0.
[16] Volpe M,Battistoni A,Rubattu S.Natriuretic peptides in heart failure: Current achievements and future perspectives[J].Int J Cardiol, 2019,281:186-189.
[17] Dickey DM,Flora DR,Bryan PM,et al.Differential regulation of membrane guanylyl cyclases in congestive heart failure:natriuretic peptide receptor (NPR)-B, not NPR-A, is the predominant natriuretic peptide receptor in the failing heart[J].Endocrinology,2007,148(7):3518-3522.
[18] Zakeri R,Sangaralingham SJ,Sandberg SM,et al.Urinary c-type natriuretic peptide:a new heart failure biomarker[J].JACC:Heart Fail,2013,1(2):170-177.
[19] Zakeri R,Burnett JC,Sangaralingham SJ.Urinary c-type natriuretic peptide:an emerging biomarker for heart failure and renal remodeling[J].Clin Chim Acta,2015,443:108-113.
[20] Sangaralingham SJ,Mckie PM,Ichiki T,et al.Circulating c-type natriuretic peptide and its relationship to cardiovascular disease in the general population[J].Hypertension,2015,65(6):1187-1194.
[21] Del Ry S,Cabiati M,Stefano T,et al.Comparison of NT-proCNP and CNP plasma levels in heart failure, diabetes and cirrhosis patients[J].Regul Pept,2011,166(1-3):15-20.
[22] Lok DJ,Klip IT,Voors AA,et al.Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction[J].Eur J Heart Fail,2014,16(9):958-966.
[23] Demissei BG,Valente MAE,Cleland JG,et al.Optimizing clinical use of biomarkers in high-risk acute heart failure patients[J].Eur J Heart Fail,2016,18(3):269-280.
[24] Del Ry S,Passino C,Maltinti M,et al.C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity[J].Eur J Heart Fail,2005,7(7):1145-1148.
[25] Del Ry S,Maltinti M,Cabiati M,et al.C-type natriuretic peptide and its relation to non-invasive indices of left ventricular function in patients with chronic heart failure[J].Peptides,2008,29(1):79-82.
[26] Li T,Cheng HJ,Ohte N,et al.C-type natriuretic peptide improves left ventricular functional performance at rest and restores normal exercise responses after heart Failure[J].J Pharmacol Exp Ther,2016,357(3):545-553.
[27] Moltzau LR,Aronsen JM,Meier S,et al.Different compartmentation of responses to brain natriuretic peptide and c-type natriuretic peptide in failing rat ventricle[J].J Pharmacol Exp Ther,2014,350(3):681-690.
[28] Meier S,Andressen KW,Aronsen JM,et al.PDE3 inhibition by C-type natriuretic peptide-induced cGMP enhances cAMP-mediated signaling in both non-failing and failing hearts[J].Eur J Pharmacol,2017,812:174-183.
[29] Wojta J.Cenderitide: a multivalent designer-peptide-agonist of particulate guanylyl cyclase receptors with considerable therapeutic potential in cardiorenal disease states[J].Eur Heart J Cardiovasc Pharmacother,2016,2(2):106-107.
相似文献/References:
[1]许少华,张曼,综述,等.晚钠电流与舒张性心力衰竭[J].心血管病学进展,2016,(2):213.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.030]
XU Shaohua,ZHANG Man,ZHANG Jin,et al.Late Sodium Current and Diastolic Heart Failure[J].Advances in Cardiovascular Diseases,2016,(5):213.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.030]
[2]孙静美 尹德春 曲秀芬.炎症信号与心房颤动[J].心血管病学进展,2020,(1):31.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.009]
SUN Jingmei,YIN Dechun,QU Xiufen.Inflammatory Signals Associated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2020,(5):31.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.009]
[3]王学文?柯元甲?赵庆彦.自主神经调控免疫重构与房颤的发生[J].心血管病学进展,2023,(7):645.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.016]
WANG Xuewen,KE Yuanjia,ZHAO Qingyan.Autonomic Nerve Regulates Immune Remodeling and The Occurrence of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2023,(5):645.[doi:10.16806/j.cnki.issn.1004-3934.2023.07.016]
[4]牟秦娇 张玥 王楠.无导线起搏器在特殊人群中植入的研究进展[J].心血管病学进展,2023,(8):694.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.006]
MOU QinjiaoZHANG YueWANG Nan.Analysis of Implantation of Leadless Pacemakers in Special Populations[J].Advances in Cardiovascular Diseases,2023,(5):694.[doi:10.16806/j.cnki.issn.1004-3934.2023.08.006]